Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 194
- 试验地点
- 10
- 主要终点
- Primary composite outcome measure - labeled Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD) -
研究概览
简要总结
Primary objective: To demonstrate the non-inferiority of acetylsalicylic acid (ASA) to anticoagulant treatment (vitamin K antagonists) in CAD-patients with regard to outcome and complication measures.
Methods: Randomized controlled, open labeled multicenter, non-inferiority trial with blinded assessment of outcome events.
Primary endpoint: Primary composite outcome measure - labeled Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD) - includes the following efficacy and safety outcome measures during the treatment period: (i) occurrence of any stroke*, new acute lesions on diffusion weighted MRI (ii) any major extracranial hemorrhage, any symptomatic intracranial hemorrhage and any asymptomatic micro- or macrobleeds, (iii) death.
详细描述
Substudies:
- In-depth analysis of the TREAT-CAD randomized trial:
The investigators will perform a subgroup analysis on the per-protocol population investigating if the antithrombotic treatment effect (anticoagulation versus aspirin) depends on specific patient baseline characteristics. The investigators will look at the following subgroups: Presenting with cerebral ischemia - either clinical ischemic events, MRI lesions, or both - versus presenting with local symptoms only, occlusion of the dissected artery at baseline (no/yes), early versus delayed treatment start (divided by the median of the study population), acute recanalization therapy including intravenous thrombolysis and/or endovascular therapy (no/yes), intracranial extension of the dissected artery (no/yes), site of dissection defined as internal carotid artery dissection versus vertebral artery dissection, single versus multivessel dissection, younger versus older age (divided by the median of the study population), and male versus female. 2. TCD Monitoring Substudy:
The objective of the TREAT-CAD transcranial Doppler (TCD) substudy is to (i) detect the frequency of microembolic signals (MES) in CAD patients, stratified to the type of treatment (aspirin vs. anticoagulation) - in the setting of an RCT (randomized controlled trial)- and (ii) to evaluate the meaning of MES by addressing the following questions: (a) Is there an association of MES (presence or number) with the occurrence of clinical and/or surrogate MR (magnetic resonance) outcome measures; (b) Is there an interaction between MES, type of treatment and outcome events. Participants are asked to allow a 6-h TCD monitoring in between day 1 and day 4 since start of the allocated study treatment. Recordings were allowed to be split in up to three episodes (2 h each). In patients with ICAD (internal carotid artery dissection), the ipsilateral middle cerebral artery is investigated. In patients with VAD (vertebral artery dissection), the ipsilateral posterior cerebral artery is investigated. 3. Biomarker substudy:
The objective of the biomarker study is to investigate whether the plasma level of MMP9 (matrix-metalloproteinase 9) and the ratio of the plasma MMP9 to TIMP2 (tissue inhibitor of metalloproteinases 2) is associated with efficacy and safety measures in CAD patients, when stratified to the allocated treatment regime. Plasma samples are collected from participants at baseline (i.e., prior to start of the allocated treatment within the TREAT-CAD main study) and at Follow-up visit 1. The specific focus on MMP9 and TIMP2 is based on preliminary observational data pointing to higher MMP9 and MMP9/TIMP2 ratios in CAD versus control patients. 4. 6 Month-follow-up for TREAT-CAD To compare (i) the frequency of clinical and MRI outcomes 6 months after cervical artery dissection among the per-protocol participants of the TREAT-CAD trial and (ii) to focus on events occurring between 3 and 6 months, stratified to the type of antithrombotic medication taken (as-treated analysis). 5. Detailed imaging analysis in the TREAT-CAD study To identify possible imaging risk factors for recurrent stroke and to evaluate the dependence of antithromobotic therapy on imaging factors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
PROBE-Design: Prospective, randomized, open-label, blinded assessment of end-points.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute ischemic or non-ischemic symptoms within 2 weeks
- •Verification of CAD-diagnosis (carotid and/or vertebral) by MR-techniques (at least one):
- •mural hematoma or
- •pseudo-aneurysm or
- •long filiform stenosis or
- •intimal flap or
- •double lumen or
- •occlusion situated more than 2 cm above the bifurcation of the carotid artery, revealing a pseudo aneurysm or a long filiform stenosis after recanalisation.
- •Written informed consent by patient or next-to-kin
- •24h latency period in case of thrombolysis
- •Age > 18 years by time of inclusion
排除标准
- •MR-contraindications (claustrophobia precluding MRI: patients agreeing to undergo MRI scanning with mild sedation may be entered into the study)
- •Contraindications to the use of anticoagulation (vitamin k antagonists, heparin) or ASA (according to the Swiss "Arzneimittelkompendium" http://www.compendium.ch/search/de or the "Rote Liste" (German centers) or "Lægemiddelstyrelsen - produktresume" for the Danish center (https://laegemiddelstyrelsen.dk/da/bivirkninger/find-medicin/produktresumeer/) and the judgment of the treating physician)
- •Pregnancy (Note: for women in child bearing age a pregnancy test has to be done prior to study entry)
研究组 & 干预措施
Oral Anticoagulation
Vitamin K-Antagonists, target INR 2.0-3.0
干预措施: Vitamin K antagonist (Drug)
Antiplatelets
Acetylsalicylic acid, 300mg o.p.d.
干预措施: Acetylsalicylic acid (Drug)
结局指标
主要结局
Primary composite outcome measure - labeled Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD) -
时间窗: 3 months
CIHD - includes the following efficacy and safety outcome measures during the treatment period: includes the following efficacy and safety outcome measures during the treatment period: (i) occurrence of any stroke (including retinal infarction), new acute lesions on diffusion weighted MRI (ii) any major extracranial hemorrhage, any symptomatic intracranial hemorrhage and any asymptomatic micro- or macrobleeds, (iii) death.
次要结局
- new acute lesions on diffusion-weighted MRI(3 months)
- any asymptomatic micro- or macrobleeds(3 months)
- new ischemic strokes (including retinal infarction)(3 months)
- any symptomatic intracranial hemorrhage(3 months)
- any major extracranial hemorrhage(3 months)
- any death(3 months)
- any increase in volume of the vessel wall hematoma at the followup cervical MRI as compared to the baseline MR-scan(3 months)
- independence in activity of daily living (modified Rankin scale 0-2) at 3 months and at 6 months(3 months)
- excellent functional outcome (modified Rankin scale 0,1) at 3 month and at 6 months(3 months)
- any TIA (classical definition)(3 months)
- recurrent cervical artery dissection(3 months)
研究者
Stefan Engelter
Prof. Dr. med., MD
University Hospital, Basel, Switzerland